IMMUNOGENESIS Trademark

Trademark Overview

On Wednesday, June 26, 2019, a trademark application was filed for IMMUNOGENESIS with the United States Patent and Trademark Office. The USPTO has given the IMMUNOGENESIS trademark a serial number of 88490659. The federal status of this trademark filing is REGISTERED as of Tuesday, December 8, 2020. This trademark is owned by Immunogenesis, Inc.. The IMMUNOGENESIS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the pharmaceutical field; biotechnology research
immunogenesis

General Information

Serial Number88490659
Word MarkIMMUNOGENESIS
Filing DateWednesday, June 26, 2019
Status700 - REGISTERED
Status DateTuesday, December 8, 2020
Registration Number6218717
Registration DateTuesday, December 8, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesResearch and development in the pharmaceutical field; biotechnology research

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, July 8, 2019
Primary Code042
First Use Anywhere DateThursday, April 30, 2020
First Use In Commerce DateThursday, April 30, 2020

Trademark Owner History

Party NameImmunogenesis, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressHouston, TX 77010
Party NameImmunogenesis, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressHouston, TX 77010

Trademark Events

Event DateEvent Description
Saturday, June 29, 2019NEW APPLICATION ENTERED
Monday, July 8, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 16, 2019ASSIGNED TO EXAMINER
Saturday, September 21, 2019NON-FINAL ACTION WRITTEN
Saturday, September 21, 2019NON-FINAL ACTION E-MAILED
Saturday, September 21, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 20, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 20, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 20, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 10, 2020NON-FINAL ACTION WRITTEN
Friday, April 10, 2020NON-FINAL ACTION E-MAILED
Friday, April 10, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 8, 2020TEAS AMENDMENT OF USE RECEIVED
Wednesday, September 9, 2020USE AMENDMENT FILED
Wednesday, September 9, 2020AMENDMENT TO USE PROCESSING COMPLETE
Tuesday, September 8, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 22, 2020ASSIGNED TO LIE
Thursday, October 22, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 22, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 23, 2020USE AMENDMENT ACCEPTED
Friday, October 23, 2020APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Saturday, October 24, 2020NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Tuesday, November 3, 2020LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, December 8, 2020REGISTERED-SUPPLEMENTAL REGISTER
Tuesday, August 10, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Tuesday, August 10, 2021WITHDRAWAL OF ATTORNEY GRANTED
Monday, December 8, 2025COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

immunogenesis research biotechnology field pharmaceutical development